BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders

BioLife Solutions , Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has entered into a definitive agr

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has successfully developed a scalable process for producing cannabigerol (" CBG ") with greater than 99% purity and no detectable THC and demonstrated production at 500 litre scale.

Pear Therapeutics, Inc. and PreferredOne announced today that reSET® and reSET-O®, the first two prescription digital therapeutics (PDTs) to receive authorization to treat disease from the U.S. Food and Drug Administration (FDA), have been added to PreferredOne’s medical benefits as covered products for its members.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the Auryon Atherectomy System, a newly-developed innovative technology for the treatment of Peripheral Artery Disease (PAD),including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR

CollPlant Biotechnologies and United Therapeutics Corporation announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys.

Agreement Includes Global Rights for Risuteganib, An Investigational Treatment Expected to Help Reverse Vision Loss Due to Dry AMD, A Significant Unmet Medical Need

Integral Molecular has been awarded $521,723 from the Commonwealth of Pennsylvania to leverage its technologies in the global fight against COVID-19.

Boston Scientific Corporation announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation system for the treatment of atrial fibrillation and other cardiac arrhythmias.